Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
NRx Pharmaceuticals (NASDAQ:NRXP) soars 9.6% premarket after announcing an additional finding in its Phase 2b/3 trial investigating ZYESAMI (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. NRx's new analysis shows that patients treat...
NRx Pharmaceuticals (NASDAQ:NRXP) soars 15.8% premarket after signing an agreement with Cardinal Health (NYSE:CAH) for third party logistics and distribution of Zyesami upon the potential Emergency Use Authorization (EUA) approval by the FDA. In May, NRx submitted an EUA a...
GENEVA, SWITZERLAND / ACCESSWIRE / August 19, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U....
NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet...
Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (OTCQB:RLFTF) have submitted of a New Drug Application (NDA) to the FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs). Acer expects to receive FDA notification on the potential acceptance within 60...
Relief Therapeutics (OTCQB:RLFTF), via its newly acquired subsidiary, AdVita Lifescience GmbH, has been granted Orphan Drug Designation by the FDA for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. Among the benefits of Orphan Drug status in the U...
Relief now has Orphan Drug Designations for Its Sarcoidosis, Epidermolysis Bullosa (EB) and Phenylketonuria (PKU) Product Candidates RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“ Relief ” or the " Company "), a biopharmaceutical company seeking...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re kicking off another busy day of trading with a dive into the biggest pre-market stock movers for Thursday. Source: Shutterstock We’re seeing a fair few companies this morning affect...
GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its coll...
Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...